NASDAQ: RLYB · Life Sciences · 6 alerts · CIK 1739410
Share price
$15.43Close, Nov 16
Market cap
$83M
Shares outstanding
5.38MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rallybio Corp filings on SEC EDGAR ↗
Rallybio Corp announced that its pending merger with Avenzo Therapeutics is expected to close following the close of trading on November 20, 2026. The company also provided a timeline update for its previously announced special cash distribution of $13.90 per share, which will be paid to stockholders of record as of November 5, 2026, following Nasdaq due bill procedures.
Rallybio announced a 1-for-2 reverse stock split effective November 20, 2026, reducing outstanding shares from 5.6 million to 2.8 million. The split is being executed in connection with its pending merger with Avenzo Therapeutics, Inc., after which the combined company will trade under the symbol AVZO. The final ratio was mutually determined by both companies following shareholder approval at the November 4, 2026, annual meeting.